Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Glioma Clinical Trial

Official title:

A Pilot Study to Evaluate the Safety and Efficacy of Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Based on the Expression of Tumor Specific/Associated Antigens

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03423992
• Other study ID #: Xuanwu hospital
• Status: Recruiting
• Phase: Phase 1
• Start date: March 2, 2018
• Est. completion date: January 30, 2023

Study information

• Verified date: June 2021
• Source: Xuanwu Hospital, Beijing
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A pilot study to determine the safety and efficacy of chimeric antigen receptor T cell (autologous T cells transduced with a lentiviral vector expressing chimeric antigen receptor with or without anti-PDL1 antibody) personalized immunotherapy for patients with recurrent malignant gliomas based on the expression of tumor specific/associated antigens (EGFRVIII, IL13Rα2, Her-2, EphA2, CD133, GD2).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: January 30, 2023
• Est. primary completion date: January 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Voluntary informed consent for entry of trial;
• Age greater than 18 years, and less than 70 years;
• Pathologically confirmed recurrent malignant gliomas;
• Tumor cells from resected tissue must be available for antigen testing (EGFRvIII, IL13Ra2, Her-2, CD133, EphA2, GD2) and at least one of the targets should be tested positively by immunohistochemistry study;
• If the patient is on dexamethasone, the anticipated dose must be 4 mg/day or less for at least 5 days prior to apheresis.
• Patients must have a Karnofsky performance status of greater than or equal to 70.
• Life expectancy greater than 3 months;
• Participants with adequate organ function as measured by:

1. White blood count greater than or equal to 2500/mm^3; platelets greater than or equal to 100,000/mm^3, hemoglobin greater than or equal to 10.0 g/dL; without transfusion or growth factor support

2. Aspartate transaminase (AST), Alanine transaminase (ALT), gamma glutamyl transpeptidase (GGT), lactic acid dehydrogenase (LDH), alkaline phosphatase within 2.5 x upper normal limit, and total bilirubin less than or equal to 2.0 mg/dL

3. Serum creatinine less than or equal to 1.5 x upper limit of normal

4. Coagulation tests prothrombin time (PT) and partial thromboplastin time (PTT) have to be within normal limits, unless the patient has been therapeutically anti-coagulated for previous venous thrombosis.

Exclusion Criteria:

• Female subjects of reproductive potential who are pregnant or lactating;
• Previous treatment with any gene therapy products or other form immunotherapy;
• Uncontrolled active infection.
• Active or latent chronic hepatitis B [detectable hepatitis B surface antigen (HBsAg)] or active hepatitis C (positive serology [hepatitis C virus Ab]) infection.
• HIV infection;
• History of allergy or hypersensitivity to study product excipients (human serum albumin, Dimethyl sulfoxide, and Dextran 40);
• Currently enrolled in other clinical trials;

Related Conditions & MeSH terms

• Glioma
• Malignant Glioma of Brain
• Recurrence
• Recurrence Tumor

Intervention

Biological:
• chimeric antigen receptor T cells
chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Ra2, Her-2, CD133, EphA2, GD2, respectively

Locations

Country	Name	City	State
China	Xuanwu Hospital	Beijing

Sponsors (4)

Lead Sponsor	Collaborator
Xuanwu Hospital, Beijing	Beijing HuiNengAn Biotech Company, Beijing Mario Biotech Company, Hebei Senlang BIotech Company

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events attributed to the administration of the chimeric antigen receptor T cells	Determine the toxicity profile of the chimeric antigen receptor T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.	1 year
Secondary	Objective Response Rate	The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline.	1 year
Secondary	clinical activity of chimeric antigen receptor T cells	the number of infused chimeric antigen receptor T cells;	28 days